ESSA Pharma (EPIX) Projected to Post Earnings on Monday

Key Points

• ESSA Pharma (NASDAQ:EPIX) is set to announce its Q3 2025 earnings on August 4th, with analysts expecting a loss of ($0.24) per share.
• In its previous quarter, ESSA Pharma reported a loss of ($0.14) EPS, beating estimates by $0.05.
• The company's stock is currently trading at $1.88, with a market cap of $83.45 million and a P/E ratio of -2.98.

ESSA Pharma (NASDAQ:EPIX - Get Free Report) TSE: EPI is projected to release its Q3 2025 earnings data before the market opens on Monday, August 4th. Analysts expect ESSA Pharma to post earnings of ($0.24) per share for the quarter.

ESSA Pharma (NASDAQ:EPIX - Get Free Report) TSE: EPI last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.05. On average, analysts expect ESSA Pharma to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

ESSA Pharma Stock Performance

NASDAQ:EPIX traded up $0.01 during trading on Thursday, reaching $1.89. The company's stock had a trading volume of 397,323 shares, compared to its average volume of 209,827. The firm has a market cap of $83.67 million, a price-to-earnings ratio of -2.99 and a beta of 1.56. The firm has a 50 day moving average of $1.75 and a 200-day moving average of $1.70. ESSA Pharma has a 12 month low of $1.40 and a 12 month high of $7.88.

ESSA Pharma Company Profile

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.